EMD 2.94% 3.3¢ emyria limited

Ann: March 2024 Quarterly Activities Report and Appendix 4C, page-16

  1. 455 Posts.
    lightbulb Created with Sketch. 73
    Load of crap. You don't just put the skids on a P3 trial if it was proving successful. Something more is going on and they are not being transparent. Obviously the trial results were not as good as they thought so they switched lanes and called it "manufacturing challenges". They didn't have manufacturing challenges when they were using the drug to capture their real life data. Tell us what's really going on.
 
watchlist Created with Sketch. Add EMD (ASX) to my watchlist
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.